BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries

European Journal of Epidemiology

Volumn 29, Issue 10, 2014, Pages 777-790

  Zeller, Tanja ^a,b   Hughes, Maria ^b,c   Tuovinen, Tarja ^d   Schillert, Arne ^b,e   Conrads Frank, Annette ^f   Ruijter, Hester den ^g   Schnabel, Renate B ^a,b   Kee, Frank ^c   Salomaa, Veikko ^d   Siebert, Uwe ^f,h   Thorand, Barbara ^b,i   Ziegler, Andreas ^b,e,j   Breek, Heico ^k   Pasterkamp, Gerard ^g   Kuulasmaa, Kari ^d   Koenig, Wolfgang ^l   Blankenberg, Stefan ^a,b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^j UNIVERSITY OF LÜBECK   (Germany)

^k Cavadis BV   (Netherlands)

^l UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

BiomarCaRE; Biomarker; Cardiovascular Risk Assessment; EU; MORGAM

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; EPIDEMIOLOGICAL DATA; EUROPE; EUROPEAN; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREVENTION STUDY; VALIDATION PROCESS; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; CAUCASIAN; COOPERATION; EUROPEAN UNION; FACTUAL DATABASE; FEMALE; FOLLOW UP; HEALTH SURVEY; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; EUROPEAN UNION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MICRORNAS; MIDDLE AGED; PILOT PROJECTS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84911993085     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9952-x     Document Type: Article

References (39)

1. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–95.
2. Arbuckle JL. Full information estimation in the presence of incomplete data. In: Marcoulides GA, Schumaker RE, editors. Advanced structural equation modeling: Issues and techniques. Mahwah, NJ: Lawrence Erlbaum Associates; 1996. p. 243–277.
3. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310–5.
4. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Munzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V, M. Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121(22):2388–97.
5. Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796–803.
6. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, S. p. group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.
7. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.
8. Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: Wiley; 1987.
9. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, Perola M, Peltonen L, Shields D, Tunstall-Pedoe H, Kuulasmaa K, M. Project. MORGAM (an international pooling of cardiovascular cohorts). Int J Epidemiol. 2005;34(1):21–7.
10. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011;31(11):2383–90.
11. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, Buysschaert I, Lambrechts D, Van de Werf F. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31(22):2755–64.
12. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011;109(4):463–74.
13. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Statist. 2008;2:841–860.
14. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther. 2011;90(1):52–66.
15. Hothorn T, Buhlmann P, Dudoit S, Molinaro A, van der Laan MJ. Survival ensembles. Biostatistics. 2006;7(3):355–73.
16. Kanhai DA, Visseren FL, van der Graaf Y, Schoneveld AH, Catanzariti LM, Timmers L, Kappelle LJ, Uiterwaal CS, Lim SK, Sze SK, Pasterkamp G, de Kleijn DP, S. S. Group. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int J Cardiol. 2013;168(3):2358–63.
17. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868–77.
18. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.
19. Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. Case-cohort design in practice—experiences from the MORGAM Project. Epidemiol Perspect Innov. 2007;4:15.
20. Kulathinal S, Niemelä M, Kuulasmaa K. Contributors from Participating Centres, for the MORGAM Project. Description of MORGAM Cohorts. MORGAM Project e-publications. Internet 2005.
21. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49–57.
22. Pedrotty DM, Morley MP, Cappola TP. Transcriptomic biomarkers of cardiovascular disease. Prog Cardiovasc Dis. 2012;55(1):64–9.
23. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012;58(1):139–47.
24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto A M Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, J. S. Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
25. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE. 2010;5(4):e10100.
26. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Munzel TF, Tiret L, Vasan RS, Blankenberg S. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010;31(24):3024–31.
27. Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, Dungan J, Newby LK, Hauser ER, Ginsburg GS, Newgard CB, Kraus WE. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3(2):207–14.
28. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110–20.
29. Siebert U. Cost-effectiveness. New York: McGraw-Hill; 2007.
30. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32(5):690–700.
31. Thomas GS, Voros S, McPherson JA, Lansky AJ, Winn ME, Bateman TM, Elashoff MR, Lieu HD, Johnson AM, Daniels SE, Ladapo JA, Phelps CE, Douglas PS, Rosenberg S. A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. Circ Cardiovasc Genet. 2013;6(2):154–62.
32. Tunstall-Pedoe H, Kuulasmaa K, Tolonen H, Davidson M, Mendis S with and o. c. f. T. W. M. Project. MONICA, Risk, Genetics, Archiving, and Monograph. MONICA Monograph and Multimedia Sourcebook. T.-P. H, Geneva: World Health Organization; 2003.
33. van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219–34.
34. Wang JW, Gijsberts CM, Seneviratna A, de Hoog VC, Vrijenhoek JE, Schoneveld AH, Chan MY, Lam CS, Richards AM, Lee CN, Mosterd A, Sze SK, Timmers L, Lim SK, Pasterkamp G, de Kleijn DP. Plasma extracellular vesicle protein content for diagnosis and prognosis of global cardiovascular disease. Neth Heart J. 2013;21(10):467–71.
35. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O’Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53.
36. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, Investigators IS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.
37. Zeller T, Blankenberg S. Blood-based gene expression tests: promises and limitations. Circ Cardiovasc Genet. 2013;6(2):139–40.
38. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, Maouche S, Germain M, Lackner K, Rossmann H, Eleftheriadis M, Sinning CR, Schnabel RB, Lubos E, Mennerich D, Rust W, Perret C, Proust C, Nicaud V, Loscalzo J, Hubner N, Tregouet D, Munzel T, Ziegler A, Tiret L, Blankenberg S, Cambien F. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. PLoS ONE. 2010;5(5):e10693.
39. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–16.